MK-2206 dihydrochloride is a potent and selective inhibitor of AKT1/2/3, which are protein kinases that play a critical role in cell growth and survival. It is used primarily in cancer treatment, where it has shown promising results in preclinical trials.
Chemical name: 8-[4-(1-Amino-1-methylethyl)phenyl]-9-phenyl-2H-benzo[h]chromen-2-one dihydrochloride Molecular formula: C32H33N2OCl2 Formula weight: 581.54 g/mol CAS No: 1032350-13-2
Top ten keywords and synonyms from Google search:
Health benefits of this product include its ability to inhibit tumor growth and induce apoptosis in cancer cells. It has also been shown to have anti-proliferative effects on various types of cancer cells. Preclinical studies have demonstrated the potential for MK-2206 to work synergistically with other anticancer agents, enhancing their effectiveness.
MK-2206 dihydrochloride works by inhibiting the AKT signaling pathway, which is activated in many cancers and is involved in regulating cell proliferation, survival, and metabolism. By blocking this pathway, MK-2206 can induce apoptosis in cancer cells and inhibit tumor growth.
Safety is an important consideration when using any therapeutic agent. Preclinical studies have shown that MK-2206 dihydrochloride has a favorable safety profile, with no evidence of significant toxicity or adverse effects at therapeutic doses. However, as with any drug, careful monitoring and dose adjustment may be needed to minimize the risk of side effects.
Common side effects associated with MK-2206 dihydrochloride include fatigue, nausea, diarrhea, and rash. These side effects are generally mild and self-limiting, and most patients tolerate treatment well.
Dosing information for MK-2206 dihydrochloride varies depending on the patient's age, weight, and medical history. It is typically administered orally once daily, and the recommended dose range is 60-600 mg/day.
In conclusion, MK-2206 dihydrochloride is a promising anticancer agent that works by inhibiting the AKT signaling pathway. It has been shown to have anti-proliferative and pro-apoptotic effects on cancer cells, making it a potential candidate for molecular targeted therapy in cancer treatment. While it has a favorable safety profile, careful monitoring and dose adjustment may be necessary to minimize the risk of side effects.